Drugs in ATC Class D07XB

Up to Top Level ATC Classes

Up to D - Dermatologicals

Up to D07 - CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

Up to D07X - CORTICOSTEROIDS, OTHER COMBINATIONS

Drugs in ATC Class: D07XB - Corticosteroids, moderately potent, other combinations

Tradename	Generic Name
MYCO-TRIACET II	nystatin; triamcinolone acetonide
MYCOLOG-II	nystatin; triamcinolone acetonide
MYKACET	nystatin; triamcinolone acetonide
MYTREX A	neomycin sulfate; triamcinolone acetonide
MYTREX F	nystatin; triamcinolone acetonide
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE	neomycin sulfate; triamcinolone acetonide
NYSTATIN AND TRIAMCINOLONE ACETONIDE	nystatin; triamcinolone acetonide

D07XB Market Analysis and Financial Projection

The market for ATC Class D07XB (corticosteroids, moderately potent, other combinations) reflects steady growth driven by rising dermatological needs and strategic formulation innovations, while its patent landscape remains dynamic but less saturated compared to other corticosteroid classes.

Market Dynamics

• Growth Projections: The global topical corticosteroids market is expected to grow at a 6.1% CAGR (2023–2030), reaching $6.4 billion by 2030[16][17]. Moderately potent corticosteroids, including D07XB combinations (e.g., with coal tar or salicylic acid), contribute to this growth due to their balanced efficacy-safety profile for conditions like eczema and psoriasis[3][8].
• Regional Dominance: North America holds ~38% market share (2022), attributed to high rates of inflammatory skin diseases (e.g., 25 million U.S. asthma patients)[15][17]. Asia-Pacific is the fastest-growing region, fueled by expanding healthcare access and rising dermatological awareness[16][18].
• Key Drivers:
  • Increasing prevalence of chronic skin conditions (e.g., 52% treatment success rate with moderate-potency corticosteroids vs. 34% for mild)[3].
  • Demand for combination therapies that reduce irritation (e.g., tazarotene + corticosteroids)[4][12].
  • Regulatory shifts, such as the British National Formulary’s reclassification of hydrocortisone butyrate 0.1% to “moderate potency,” influencing prescribing trends[11].

Patent Landscape

• Competitive Activity: Over 6,927 patent applications are linked to corticosteroids broadly, with D07XB-specific combinations involving flumethasone, triamcinolone, and dexamethasone[1][10][13]. Key players include GlaxoSmithKline, Pfizer, and Merck, alongside emerging Chinese suppliers[1][7][15].
• Innovation Trends:
  • Formulation Optimization: Patents focus on enhancing stability and bioavailability (e.g., halobetasol + tazarotene combinations)[4][12].
  • Synergistic Combinations: Clinical trials highlight additive effects of corticosteroids paired with keratolytics (e.g., salicylic acid)[14].
• Challenges:
  • Patent Expirations: Over 87 bulk API suppliers for dexamethasone sodium phosphate intensify generic competition[1].
  • Regulatory Complexity: Discrepancies in potency classification (e.g., betamethasone valerate 0.025% now labeled “potent” in the UK)[11] complicate IP strategies.

Strategic Insights

• Opportunities: Developing novel combinations (e.g., corticosteroids + carbamide) to address underserved conditions like psoriasis[14].
• Risks: Non-practicing entities (NPEs) entering the patent landscape could trigger litigation, particularly in high-growth regions like Asia[7].

The D07XB segment remains a critical niche, balancing efficacy with reduced systemic exposure. Companies investing in differentiated combinations and robust IP frameworks are poised to capitalize on this $8.19 billion market by 2030[18].

References

1. https://www.drugpatentwatch.com/p/generic-api/DEXAMETHASONE+SODIUM+PHOSPHATE
2. https://www.ipstudies.ch/2017/06/june-2017-acceleration-of-the-crispr-patent-landscape-growth/
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC8916090/
4. https://www.govinfo.gov/content/pkg/USCOURTS-njd-2_20-cv-05426/pdf/USCOURTS-njd-2_20-cv-05426-4.pdf
5. https://en.wikipedia.org/wiki/ATC_code_D07
6. https://atcddd.fhi.no/filearchive/publications/2025_guidelines__final_web.pdf
7. https://www.knowmade.com/patent-analytics-services/patent-report/semiconductor-patent-landscape/semiconductor-memory-patent-landscape/3d-non-volatile-memory-patent-landscape/
8. https://www.databridgemarketresearch.com/reports/north-america-topical-corticosteroids-market
9. https://go.drugbank.com/drugs/DB00663
10. https://go.drugbank.com/drugs/DB00620
11. https://www.bmj.com/content/386/bmj.q1893/rr-1
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC8466269/
13. https://pubchem.ncbi.nlm.nih.gov/compound/Flumethasone
14. https://atcddd.fhi.no/atc_ddd_index/?code=D07XB30
15. https://www.mordorintelligence.com/industry-reports/corticosteroids
16. https://www.databridgemarketresearch.com/reports/global-topical-corticosteroids-market
17. https://www.evalueserve.com/patent-analysis/
18. https://www.sphericalinsights.com/reports/topical-corticosteroids-market